APA (7th ed.) Citation

Konecny, G., Moore, K., Lebreton, C., Weroha, S., Marin, M. R., McAvan, L., . . . Van Gorp, T. (2024). Patient-reported outcome results from phase III MIRASOL trial of mirvetuximab soravtansine versus investigator's choice of chemotherapy in FRα-positive, platinum-resistant ovarian cancer. Gynecologic Oncology, 190, S11. https://doi.org/10.1016/j.ygyno.2024.07.023

Chicago Style (17th ed.) Citation

Konecny, Gottfried, et al. "Patient-reported Outcome Results from Phase III MIRASOL Trial of Mirvetuximab Soravtansine Versus Investigator's Choice of Chemotherapy in FRα-positive, Platinum-resistant Ovarian Cancer." Gynecologic Oncology 190 (2024): S11. https://doi.org/10.1016/j.ygyno.2024.07.023.

MLA (9th ed.) Citation

Konecny, Gottfried, et al. "Patient-reported Outcome Results from Phase III MIRASOL Trial of Mirvetuximab Soravtansine Versus Investigator's Choice of Chemotherapy in FRα-positive, Platinum-resistant Ovarian Cancer." Gynecologic Oncology, vol. 190, 2024, p. S11, https://doi.org/10.1016/j.ygyno.2024.07.023.